炎症性肠病的生物标志物进展

Progress in Biomarkers of Inflammatory Bowel Disease

炎症性肠病(inflammatory bowel disease, IBD)的发病率持续攀升,预计2025年我国IBD患者将达150万例,其诊断目前需要结合临床、实验室检查、影像学检查、内镜检查和组织病理学表现进行综合分析,血液与粪便来源的生物标志物侵入性低、可重复性高,在疾病诊疗的过程中起到重要的作用。本文对IBD生物标志物的应用现状、前沿新发现的生物标志物等方面的研究进行综述,总结目前研究在疾病诊疗中的应用,旨在更好地为临床应用提供参考,提高生物标志物诊疗的准确性。

The incidence of inflammatory bowel disease (IBD) continues to climb, and it is expected that the number of IBD patients in China will reach 1.5 million cases in 2025, and its diagnosis currently requires a comprehensive analysis combining clinical, laboratory examination, imaging, endoscopy and histopathological manifestations. Biomarkers of blood and faecal origin are less invasive and more reproducible, and play an important role in the diagnosis and treatment of the disease. In this paper, we review the current status of IBD biomarkers and the newly discovered biomarkers, summarise the application of the current research in the diagnosis and treatment of IBD, and aim to provide a better reference for clinical application and improve the accuracy of biomarker diagnosis and treatment.